Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICI-5: Durvalumab vs Target Therapy in Advanced HCC
NCT03899428Phase 2Recruiting
- Sponsor
- Humanity & Health Medical Group
- Start
- May 2019
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in hepatocellular carcinoma (HCC), sponsored by Humanity & Health Medical Group. Started May 2019; status: recruiting.
02
Drugs
durvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03899428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899428.